株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

細胞療法の世界市場:治験動向、各種治療の料金動向、市場機会の分析

Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026

発行 KuicK Research 商品コード 825106
出版日 ページ情報 英文 1200 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.87円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
細胞療法の世界市場:治験動向、各種治療の料金動向、市場機会の分析 Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026
出版日: 2019年04月19日 ページ情報: 英文 1200 Pages
概要

当レポートでは、世界の細胞療法の市場・技術動向と将来展望について分析し、細胞療法の特色や利点、主な活用分野、今後の市場動向の見通し、細胞別・疾患別・地域別の詳細動向、主要企業のプロファイルと代表的製品、主な上市済み/治験中の製品のパイプライン情報、治療料金の傾向、主な市場促進・抑制要因、今後の技術開発・市場成長の方向性、といった情報を取りまとめてお届けいたします。

第1章 細胞療法の概要

第2章 細胞療法の種類

  • 同種細胞療法
  • 自己細胞療法
  • ヒト胚性幹細胞 (ES細胞) 治療
  • 神経幹細胞治療
  • 間葉系幹細胞治療
  • 造血幹細胞移植

第3章 細胞療法における治療作用の機序

第4章 細胞療法製品の製造方法

  • 細胞療法製品の製造モデル
  • GMP (適正製造基準) のための施設

第5章 従来型治療法に対する細胞療法の利点

  • アンチエイジング
  • その他の疾患への対処

第6章 個別化細胞療法

  • 個別化細胞療法の概要
  • エピジェネティク・ツールを用いた個別化細胞療法
  • 間葉系幹細胞による個別化細胞療法
  • iPS細胞によるパーキンソン病の治療
  • ケーススタディ:自己歯髄由来幹細胞・L-PRF (多白血球/多血小板フィブリン) を用いた、歯髄炎向け個別化細胞療法

第7章 細胞療法の活用分野:治療領域別

  • 心血管疾患
  • 神経障害
  • 炎症性疾患
  • 糖尿病
  • がん

第8章 世界の細胞療法市場の将来展望

  • 現在の市場シナリオ
  • 細胞療法市場:細胞の供給源別
    • iPS細胞 (人工多能性幹細胞)
    • 骨髄
    • 臍帯血由来細胞
  • 細胞療法の治験パイプライン:概略 (企業、症状、地域)

第9章 米国市場:細胞療法治療薬の投与量・コスト分析

  • Allocord
  • Laviv
  • Maci
  • Clevecord
  • Hemacord
  • Ducord
  • Provenge
  • HPC (造血前駆細胞)・臍帯血 (Clinimmune Labs、University of Colorado Cord Blood Bank)
  • HPC・臍帯血 (LifeSouth Community Blood Centers, Inc)
  • HPC・臍帯血 (Bloodworks)
  • HPC・臍帯血 (MD Anderson Cord Blood Bank)
  • Gintuit
  • Kymriah
  • Yescarta
  • Carticel

第10章 韓国市場:細胞療法治療薬の投与量・コスト分析

  • Cartistem
  • Chondron
  • KeraHeal
  • Cellgram
  • Cure Skin Injection

第11章 オーストラリア・欧州・日本市場:細胞療法治療薬の投与量・コスト分析

  • Holoclar (欧州)
  • Yescarta (欧州)
  • Kymriah (欧州)
  • Temcell HS (日本)
  • Chondrocytes-T-Ortho-ACI (オーストラリア)

第12章 細胞療法市場の動向:地域別

  • 米国
  • 韓国
  • 欧州
  • 日本
  • 中国
  • 他の国々 (RoW)
  • アフリカ
  • 中東
  • 南米

第13章 細胞療法の利点

  • 慢性リンパ性白血病に対する薬物治療の進化
  • サイトメガロウイルス感染症の予防・治療方法の進化
  • パーキンソン病向け幹細胞治療
  • アルツハイマー病向け幹細胞治療
  • 幹細胞治療によるリウマチ性関節炎の治療
  • 不妊治療における幹細胞治療の役割
  • 眼病向け幹細胞
  • 脳卒中・狭心症向け細胞療法
  • しわ・挫創瘢痕向け幹細胞治療

第14章 制御性T細胞 - 次世代の細胞療法

  • 制御性T細胞:概略
  • 制御性T細胞の分離と増殖
  • 作用機序
  • 制御性T細胞療法の治験動向
    • GvHD (移植片対宿主病) 予防のための、制御性T細胞を用いた養子的細胞療法
    • 固形臓器移植拒絶症の予防のための、ポリクローナル/同種抗原特異性・制御性T細胞を用いた養子的細胞療法
  • 自己炎症疾患・自己免疫疾患の治療用の制御性T細胞療法
    • 炎症性腸疾患 (IBD)
    • 全身性エリテマトーデス (SLE)
    • 自己免疫性肝炎
    • 尋常性天疱瘡 (PV)
    • アレルギー・喘息
    • 制御性T細胞の将来展望

第15章 世界の細胞療法市場のダイナミクス

  • 市場促進要因
  • 商業面での課題

第16章 世界の細胞療法市場:将来展望

第17章 上市済み細胞療法製品の分析:企業別・症状別

  • Tisagenlecleucel (Kymriah)
  • Axicabtagene Ciloleucel (Yescarta)
  • 同種培養角化細胞・繊維芽細胞 (Gintuit)
  • 脂肪幹細胞治療 (Adipocell (Anterogen), Cupistem & Queencell)
  • Tonogenchoncel-L (INVOSSA-K inj)
  • 間葉系幹細胞治療 (Stempeucel)
  • Remestemcel-L (Prochymal & TEMCELL HS Inj.)
  • Sipuleucel-T (Provenge)
  • 自己間葉系幹細胞 - Pharmicell
  • 自己培養軟骨細胞 (MACI)
  • 自己培養軟骨細胞 (Chondrotransplant DISC)
  • 自己角膜上皮幹細胞治療 (Holoclar)
  • Nalotimagene Carmaleucel (Zalmoxis)
  • 軟骨修復用間葉系幹細胞治療 (Cartistem)
  • 自己軟骨移植 - TETEC
  • 筋肉由来自己幹細胞治療 (MyoCell)
  • ヒト皮膚置換 (CellSpray)
  • 白血球幹細胞 (CureXcell)
  • 自己培養軟骨移植 (Carticel)
  • Azficel-T (Laviv)
  • 自己培養軟骨 (CHONDRON)
  • 自己培養軟骨 (BioCart)
  • 羊膜細胞療法 (NuCel)
  • 樹状細胞刺激型サイトカイン誘発キラー細胞 - Shanghai Jia Fu Medical
  • 自己培養筋芽細胞・繊維芽細胞 (Urocell)

第18章 世界の細胞療法市場の治験パイプライン:企業別・症状別・相 (フェーズ) 別

第19章 競争環境

  • Athersys Inc.
  • Baxter Healthcare Corporation
  • Bone Therapeutics
  • Celgene Corporation
  • Cell Medica
  • Cellerant Therapeutics
  • FibrocellScinence
  • Genzyme Corporation
  • Green Cross Cell
  • Histogenics Corporation
  • Intrexon Corporation
  • Intercytex
  • ISTO Biologics
  • Macrocure
  • Mesoblast
  • Molmed
  • Nuo Therapeutics Inc
  • OmniCyte
  • Opexa Therapeutics
  • Organogenesis
  • Pharmicell
  • TCA Cellular Therapy
  • Stem Cell Inc.
  • Teva Pharmaceuticals
  • Tigenix
  • Vericel Corporation
目次

"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights:

  • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026
  • Cell Therapy Clinical Trial Insight by Indication, Company & Country
  • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies
  • Globally Marketed Cell Therapies: 25 Cell Therapies
  • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies
  • Price & Product Insight By Region/Country
  • Regional Analysis of the Cell Therapy Market

In recent years, there has been a steady increase in the interest shown in the cell therapy segment from big pharmaceutical, biotech and medical device companies. Earlier, the idea for altering a cell or a gene to cure or treat a disease was considered impossible. But with the ongoing advancements, it has now become possible in the treatment or cure of a disease with the help of cell therapy.

Cell therapies are still in the early stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that consideration will be given on how these therapies will be carried out and subsequently be delivered to the patients on a clinically relevancy scale.

Currently, there are more than 750 cell based therapies in clinical pipeline. Most of the cell therapies are in Preclinical phase followed by Phase-I clinical trials. Analysis of the pipeline shows that majority of the cell therapy products that are currently under development are targeted towards treatment of complex disease like cardiovascular disease, neural disease and cancer. More than 20 cell therapies are commercially available in the market. However, when it comes to marketed products, more than half of the products that are currently available are in the tissue and skin treatment segment such as Apligraf and Dermigraf.

Few cell therapy products such as Kymriah, Provenge and Yescarta have emerged as the most promising therapeutics of the decade with excellent result in treatment of various clinical indications, but the market remains widely untapped due to the high price tag.

The cell therapy technique finds wide usage in almost all types of therapeutic areas. However, majority of the cell therapy research is currently being done in the cancer, Neurological, Cardiovascular and Inflammatory segments due to their high mortality rate among the global population. Few cell therapy research is being done in the diabetic segment too where the aim is to develop an artificial pancreas using cell therapy which would work just like a natural pancreas.

Cell therapies will also have the potential to replace many risky, costly and invasive surgeries. For many disease conditions, such as diabetes, patients are required to take a prescription on a daily basis. A cell therapy approach will substantially reduce the healthcare costs of this disease by providing a one-time treatment. In the same way cell therapy approaches to pain management will also reduce the costs of opioid-based pain medications. Cell therapy, in combination with the recent advances in iPS cell generation and CRISPR-Cas 9, also has a great opportunity in the future.

The path towards the success for cell therapy will consist of a combination of scenarios that is being imagined for the cure of diseases and is hoped that these will definitely come true in the near future. The advantages and risks of current cell therapy practices will improve translational success and accelerate clinical development of safe and efficient cell products in the future.

Table of Contents

1. Overview of Cell Therapy

  • 1.1. Introduction to Cell Therapy
  • 1.2. History & Evolution of Cell Therapy

2. Types of Cell Therapy

  • 2.1. Allogeneic Cell Therapy
  • 2.2. Autologous Cell Therapy
  • 2.3. Human Embryonic Stem Cell Therapy
  • 2.4. Neural Stem Cell Therapy
  • 2.5. Mesenchymal Stem Cell Therapy
  • 2.6. Hematopoietic Stem Cell Transplantation

3. Mechanism of Therapeutic Action in Cell Therapy

4. Manufacturing of Cell Therapies

  • 4.1. Models for Manufacturing Cell Therapies
  • 4.2. Facilities for Good Manufacturing Practice

5. Advantages of Cell Therapy Over Conventional Therapy

  • 5.1. Anti-Aging with Cell Therapy
  • 5.2. Addressing Other Diseases with Cell Therapy

6. Personalized Cell Therapy

  • 6.1. Overview of Personalized Cell Therapy
  • 6.2. Personalized Cell Therapy Using Epigenetic Tools
  • 6.3. Personalized Cell Therapy through Mesenchymal Stem Cells
  • 6.4. Treatment of Parkinson's Disease through IPSCs
  • 6.5. Case Study: Personalized Cell Therapy for Pulpitis Using Autologous Dental Pulp Stem Cells & Leukocyte Platelet Rich Fibrin

7. Cell Therapy Application by Therapeutic Areas

  • 7.1. Cardiovascular Disease
  • 7.2. Neurological Disorders
  • 7.3. Inflammatory Diseases
  • 7.4. Diabetes
  • 7.5. Cancer

8. Global Cell Therapy Market Outlook

  • 8.1. Current Market Scenario
  • 8.2. Cell Therapy Market by Cell Source
    • 8.2.1. Induced Pluripotent Stem Cell (IPSCs)
    • 8.2.2. Bone Marrow
    • 8.2.3. Umbilical Cord Blood Derived Cells
  • 8.3. Global Cell Therapy Clinical Pipeline (Company,Indication, Region) Overview

9. US - Cell Therapy Dosage & Cost Analysis

  • 9.1. Allocord
  • 9.2. Laviv
  • 9.3. Maci
  • 9.4. Clevecord
  • 9.5. Hemacord
  • 9.6. Ducord
  • 9.7. Provenge
  • 9.8. HPC, Cord Blood (Clinimmune Labs, University of Colorado Cord Blood Bank)
  • 9.9. HPC, Cord Blood (LifeSouth Community Blood Centers, Inc)
  • 9.10. HPC, Cord Blood (Bloodworks)
  • 9.11. HPC, Cord Blood (MD Anderson Cord Blood Bank)
  • 9.12. Gintuit
  • 9.13. Kymriah*
  • 9.14. Yescarta*
  • 9.15. Carticel

10. South Korea - Cell Therapy Dosage & Cost Analysis

  • 10.1. Cartistem
  • 10.2. Chondron
  • 10.3. KeraHeal
  • 10.4. Cellgram
  • 10.5. Cure Skin Injection

11. Australia, Europe & Japan - Cell Therapy Dosage & Cost Analysis

  • 11.1. Holoclar (Europe)
  • 11.2. Yescarta (EU)
  • 11.3. Kymriah (EU)
  • 11.4. Temcell HS (Japan)
  • 11.5. Chondrocytes-T-Ortho-ACI (Australia)

12. Cell Therapy Market Trends: Geographically

  • 12.1. US
  • 12.2. South Korea
  • 12.3. Europe
  • 12.4. Japan
  • 12.5. China
  • 12.6. Rest of the World
  • 12.6.1. Africa
  • 12.6.2. Middle East
  • 12.6.3. South America

13. Advancements in Cell Therapy

  • 13.1. Drug Based Therapies Advancements in Chronic Lymphocytic Leukemia
  • 13.2. Advances in Cytomegalovirus Infection Prevention & Treatment
  • 13.3. Stem Cell Therapy for the Treatment of Parkinson's Disease
  • 13.4. Stem Cell Therapy for the Treatment of Alzheimer's Disease
  • 13.5. Treatment of Rheumatoid Arthritis via Stem Cell Therapy
  • 13.6. Role of Stem Cell Therapy in Treating Infertility
  • 13.7. Stem Cells for Eye Diseases
  • 13.8. Cell Therapy for Stroke and Angina Pectoris
  • 13.9. Stem Cell Therapy in Improving Wrinkles & Acne Scars

14. Treg Cells - The Next Edge of Cell Therapy

  • 14.1. Introduction to Treg Cell
  • 14.2. Isolation & Expansion of Treg Cell
  • 14.3. Mechanism of Action
  • 14.4. Clinical Trials of Treg Cell Therapy
    • 14.4.1. Adoptive Cell Therapy of Treg cells to Prevent GvHD
    • 14.4.2. Adoptive Cell Therapy of Polyclonal & Alloantigen-specific Treg cells to Prevent Solid Organ Transplant Rejection
  • 14.5. Treg Cell Therapy for the Treatmet of Autoinflammatory & Autoimmune Diseases
    • 14.5.1. Inflammatory Bowel Disease
    • 14.5.2. Systemic Lupus Erythematosus
    • 14.5.3. Autoimmune Hepatitis
    • 14.5.4. Pemphigus Vulgaris
    • 14.5.5. Allergy and Asthma
    • 14.6. Future Prospects of Treg Cell Therapy

    15. Global Cell Therapy Market Dynamics

    • 15.1. Market Drivers
    • 15.2. Commercial Challenges

    16. Global Cell Therapy Market Future Prospects

    17. Marketed Cell Therapies Clinical Insight by Company & Indication

    • 17.1. Tisagenlecleucel (Kymriah)
    • 17.2. Axicabtagene Ciloleucel (Yescarta)
    • 17.3. Allogeneic Cultured Keratinocytes And Fibroblasts (Gintuit)
    • 17.4. Adipose Stem Cell Therapy (Adipocell (Anterogen), Cupistem & Queencell)
    • 17.5. Tonogenchoncel-L (INVOSSA-K inj)
    • 17.6. Mesenchymal Stem Cell Therapies (Stempeucel)
    • 17.7. Remestemcel-L (Prochymal & TEMCELL HS Inj.)
    • 17.8. Sipuleucel-T (Provenge)
    • 17.9. Autologous Mesenchymal Stem Cell Therapy - Pharmicell
    • 17.10. Autologous Cultured Chondrocytes (MACI)
    • 17.11. Autologous Cultured Chondrocytes (Chondrotransplant DISC)
    • 17.12. Autologous Corneal Epithelial Stem Cell Therapy (Holoclar)
    • 17.13. Nalotimagene Carmaleucel (Zalmoxis)
    • 17.14. Mesenchymal Stem Cell Therapy For Cartilage Repair (Cartistem)
    • 17.15. Autologous Chondrocyte Implant - TETEC
    • 17.16. Muscle-Derived Autologous Stem Cell Therapy (MyoCell)
    • 17.17. Human Skin Replacement (CellSpray)
    • 17.18. Leukocyte Cell Therapy (CureXcell)
    • 17.19. Autologous Cultured Chondrocyte Implant (Carticel)
    • 17.20. Azficel-T (Laviv)
    • 17.21. Autologous Cultured Chondrocytes (CHONDRON)
    • 17.22. Autologous Chondrocytes (BioCart)
    • 17.23. Amniotic Cell Therapy (NuCel)
    • 17.24. Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical
    • 17.25. Autologous Cultured Myoblasts And Fibroblasts (Urocell)

    18. Global Cell Therapy Clinical Pipeline by Company, Indication & Phase

    • 18.1. Research
    • 18.2. Preclinical
    • 18.3. Clinical
    • 18.4. Phase-0
    • 18.5. Phase-I
    • 18.6. Phase-I/II
    • 18.7. Phase-II
    • 18.8. Phase-II/III
    • 18.9. Phase-III
    • 18.10. Preregistration
    • 18.11. Registered

    19. Competitive Landscape

    • 19.1. Athersys Inc.
    • 19.2. Baxter Healthcare Corporation
    • 19.3. Bone Therapeutics
    • 19.4. Celgene Corporation
    • 19.5. Cell Medica
    • 19.6. Cellerant Therapeutics
    • 19.7. FibrocellScinence
    • 19.8. Genzyme Corporation
    • 19.9. Green Cross Cell
    • 19.10. Histogenics Corporation
    • 19.11. Intrexon Corporation
    • 19.12. Intercytex
    • 19.13. ISTO Biologics
    • 19.14. Macrocure
    • 19.15. Mesoblast
    • 19.16. Molmed
    • 19.17. Nuo Therapeutics Inc
    • 19.18. OmniCyte
    • 19.19. Opexa Therapeutics
    • 19.20. Organogenesis
    • 19.21. Pharmicell
    • 19.22. TCA Cellular Therapy
    • 19.23. Stem Cell Inc.
    • 19.24. Teva Pharmaceuticals
    • 19.25. Tigenix
    • 19.26. Vericel Corporation

List of Figures

  • Figure 1-1: Cell Therapy Pathway
  • Figure 1-2: Evolution of Cell Therapy
  • Figure 2-1: Types of Cell Therapy
  • Figure 2-2: Steps in Allogeneic Cell Therapy
  • Figure 2-3: Steps in Autologous Cell Therapy
  • Figure 2-4: Steps in the Derivation of Human Embryonic Stem Cells
  • Figure 2-5: Cardinal Neural Stem Cell Properties
  • Figure 2-6: Mesenchymal Stem Cells Therapy Process
  • Figure 3-1: Cell Therapy Mechanism
  • Figure 4-1: Centralized Manufacturing Model
  • Figure 4-2: Near Patient Manufacturing Model
  • Figure 5-1: Major Steps in Cell Therapy
  • Figure 5-2: Global- Expected Aging Population of 60+ (Billion), 2015 & 2050
  • Figure 5-3: Advantages of Cell Therapy as a Rejuvenation Therapy
  • Figure 6-1: Advantages of Personalized Cell Therapy
  • Figure 6-2: Mesenchymal Stem Cells (MSCs) in Autism Spectrum Disorder (ASD) Treatment
  • Figure 6-3: Steps of iPSC Transplantation
  • Figure 7-1: Global - Mortality Caused by Non Communicable Disease (%), 2018
  • Figure 7-2: Cell Therapy for Cardiovascular Disease
  • Figure 7-3: Overview of Stem Cell Therapy in Cardiovascular Disease
  • Figure 7-4: Cell Therapy in Neurological Disorders
  • Figure 7-5: Cell Therapy in Treatment of Alzheimer's disease
  • Figure 7-6: Cell Therapy in Diabetes
  • Figure 8-1: Cell Therapy- The Final Therapeutic Pillar of Healthcare
  • Figure 8-2: Global - Cell Therapy Market (US$ Billion), 2018 - 2026
  • Figure 8-3: Process for Conventional Drug Delivery
  • Figure 8-4: Process for Induced Pluripotent Stem Cell Based Drug Delivery
  • Figure 8-5: Global- Induced Pluripotent Stem Cell Therapy Market (US$ Million), 2018 - 2026
  • Figure 8-6: Steps involved in Bone Marrow Transplant
  • Figure 8-7: Global - Cell Therapies Clinical Pipeline by Phase (%), 2019 till 2026
  • Figure 8-8: Global - Cell Therapies Clinical Pipeline by Phase (Number), 2019 till 2026
  • Figure 8-9: Global - Cell Therapies Clinical Pipeline by Region (Number), 2019 till 2026
  • Figure 8-10: Global - Cell Therapies Clinical Pipeline by Region (Number), 2019 till 2026
  • Figure 8-11: Global - Cell Therapies Clinical Pipeline by Company (Number), 2019
  • Figure 8-12: Global - Cell Therapies Clinical Pipeline by Indication (Number), 2019
  • Figure 9-1: US - Allocord Infusion per Hour (Millilitres), Adult & Children
  • Figure 9-2: US - Laviv Average Injection Cost of Initial & Whole Session (US$), March'2019
  • Figure 9-3: US - Maci Cost Comparision over Mosaicplasty & Microfracture (US$)
  • Figure 9-4: US - Clevecord Dosage of Nucleated Cells per Killogram (Million) & Average Cost (US$)
  • Figure 9-5: US - Provenge Cost of Single Infusion vs Overall Cost (US$), July 2017
  • Figure 9-6: US - Kymriah Average Dosage of CAR positive viable T cells (Paediatric & Adults), August 2017
  • Figure 9-7: US - Kymriah Treatment Cost for Leukemia & Lymphomas (US$), July 2018
  • Figure 9-8: US - Yescarta Target Dose vs Maximum Dose of CAR-positive viable T cells, October 2017
  • Figure 9-9: US - Yescarta & Kymriah Overall Treatment Cost (US$), April 2018
  • Figure 9-10: US - Yescarta & Kymriah Estimated Payment Rate by Centers for Medicare and Medicaid Services (US$), April, 2018
  • Figure 9-11: US - Carticel Minimum & Maximum Cost (US$), October 2017
  • Figure 10-1: South Korea - Cartistem Dosage (Microlitres per cm2) & Cost (US$), October 2017
  • Figure 10-2: South Korea - Chondron Dosage (Millilitres per Vial) & Cost (US$), March 2019
  • Figure 10-3: South Korea - KeraHeal vs KeraHeal-Allo Dosage form (Miililitres Cell Suspension)
  • Figure 10-4: South Korea - Cellgram Dosage (Cells per 10 Millilitre) & Cost (US$), October 2017
  • Figure 11-1: Europe - Holoclar Minimum & Maximum Dosage (Cells per cm2) & Cost (US$), August' 2017
  • Figure 11-2: European Union - Yescarta Dosage of CAR-positive viable T cells by Body Weight
  • Figure 11-3: European Union - Yescarta & Kymriah Treatment Cost for acute lymphoblastic leukaemia and diffuse large B-cell lymphoma (US$), August' 2018
  • Figure 11-4: Japan - Temcell Dosage of Cells per Killogram Body Weight (Million)
  • Figure 11-5: Japan - Temcell Total Cost vs Cost per Bag (US$), October' 2017
  • Figure 11-6: Australia - Ortho-ACI Constituents of Dulbecco's Modified Eagle Medium (DMEM) nutrient mixture
  • Figure 11-7: Australia - Ortho-ACI Average Dose (Million Cells) & Cost of Treatment (US$)
  • Figure 12-1: Significance of Cell Therapy Market Technology
  • Figure 12-2: Drivers for Growth of Cell Therapy in Japan
  • Figure 12-3: Criteria Impacting Successful Cell Therapy
  • Figure 12-4: China Cell Therapy Market Strategy
  • Figure 12-5: Rest of the World - Cell Therapy Clinical Trial by Region (%), 2019
  • Figure 13-1: Signaling Pathway in Chronic Lymphocytic Leukemia
  • Figure 13-2: Advantages of Treating Rheumatoid arthritis with Umbilical Cord Mesenchymal Stem Cells
  • Figure 13-3: Stem Cell Therapy for the Treatment of Male Infertility
  • Figure 13-4: Cell Therapy for Ptients with Angina
  • Figure 13-5: Benefits of Stem Cell Therapy in Aesthetic Purposes
  • Figure 14-1: Working of CD4+ & CD25+ Regulatory T-Cell
  • Figure 14-2: Mechanism of Action of Treg Cell
  • Figure 14-3: Therapeutic Action of Treg Cell
  • Figure 14-4: Future Applications of Treg Cells
  • Figure 15-1: Global - Key Factors Driving the Cell Therapy Market
  • Figure 15-2: Global - Cell Therapy Market Challenges
  • Figure 16-1: Growth Opportunities for Cell Therapy
  • Figure 19-1: Bone Therapeutics Clinical Pipeline
  • Figure 19-2: Celgene Clinical Pipeline
  • Figure 19-3: Cell Medica Therapeutics Clinical Pipeline
  • Figure 19-4: Cellerant Therapeutics Clinical Pipeline
  • Figure 19-5: Fibrocell Science Clinical Pipeline
  • Figure 19-6: Intrexon Clinical Pipeline
  • Figure 19-7: Mesoblast Clinical Pipeline
  • Figure 19-8: Molmed Clinical Pipeline
  • Figure 19-9: Tigenix Clinical Pipeline
  • Figure 19-10: Vericel Corporation Clinical Pipeline

List of Tables

  • Table 2-1: Difference between Allogeneic & Autologous Cell Therapy
  • Table 5-1: Difference between Cell Therapy & Conventional Therapy
  • Table 13-1: Targeted Therapy in Patients with Chronic Lymphocytic Leukemia
  • Table 13-2: Targeted Therapy in Patients with Chronic Lymphocytic Leukemia
  • Table 13-3: Results of Phase I-II Trials of Adoptive Cell Therapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant
  • Table 14-1: Functions of Effector T-Cell & Treg Cell
Back to Top